Article Text


Probiotics in IBD: mucosal and systemic routes of administration may promote similar effects
  1. B Foligné,
  2. C Grangette,
  3. B Pot
  1. Bactériologie des Ecosystèmes, Institut Pasteur de Lille, Lille, France
  1. Correspondence to:
    Dr B Pot
    Institut Pasteur de Lille, 1 Rue du Prof Calmette, BP 245, F-59019 Lille, France;

Statistics from

We read with considerable interest the paper by Sheil et al (Gut 2004;53:694–700) who reported the successful application of the subcutaneous route for probiotic attenuation of colitis.

We agree with the corresponding commentary of Ghosh et al (Gut 2004;53:620–2) regarding the need to study mechanisms underlying probiotic interactions. Recently, we further standardised a method to compare the anti-inflammatory potential of orally administered lactic acid bacteria (LAB) in a murine model of acute 2,4,6, trinitrobenzene sulphonic acid (TNBS) induced colitis.1 This model allowed us to discriminate “protective” strains, showing between 30% and 70% reduction of inflammatory score, from strains which did not significantly attenuate experimental colitis. We could select highly performing strains of Lactobacillus salivarius and Lactobacillus rhamnosus that consistently lowered colitis. In comparison, a strain of Lactobacillus acidophilus, Lactococcus lactis, and Streptococcus gordonii never showed any improvement. For all five strains, we investigated the protective effect of a single intraperitoneal injection of 5×107 live microorganisms, 24 hours prior to induction of colitis. Surprisingly, protection by the LAB strains via this systemic route closely matched the efficiency of the oral route (fig 1).

Figure 1

 Lactic acid bacteria (LAB) protection on macroscopic damages induced by 2,4,6, trinitrobenzene sulphonic acid (TNBS): the impact of the oral or intraperitoneal route of LAB administration on reduction of TNBS induced colitis in mice. Results are expressed as per cent reduction of mean macroscopic inflammation7 of mice treated with LAB, in relation to the mean score of non-treated mice. Colitis index was assessed 48 hours after TNBS administration. Each bar represents an independent experiment of control (n = 10) and LAB treated mice (n = 10). *p<0.05, **p<0.01, ***p<0.001, significantly different from the corresponding TNBS control group (Mann-Whitney U test). CFU, colony forming unit; d; day.

When evaluating both routes simultaneously, the anti-inflammatory effect was of comparable magnitude. Moreover, the prophylactic impact of the intraperitoneal Lactobacillus salivarius strain was established up to two hours before TNBS administration. It is noteworthy that two delayed injections could lead to protection but caused marked weight loss (23% (p<0.05) v 15% and 11%, respectively, for control and oral route groups) with alleged fever.

Our findings clearly confirm those of Sheil et al (Gut 2004;53:694–700) showing strain specific in vivo probiotic effects distant from the target tissue, suggesting a relationship between the type of LAB (or LAB components) and peritoneal immunocompetent cells. Pereyra and colleagues2 reported transient dose dependant induction of a/b-like interferon in serum of intraperitoneal injected Lactobacillus bulgaricus while Streptococcus thermophilus did not. Recent observations showed that heat treatment of an orally administered probiotic cocktail abolished the colitis protection in a DSS model, while irradiation improved it.3 Consequently, cellular integrity appears to be necessary to explain at least some part of the effect, although cell walls and peptidoglycans of killed bacteria cannot be considered as passive. Possibly both “good” and “bad” signals are given out by LAB, and the immune system is integrating all of them. Those “mixed” signals will no doubt be specific for each strain as well as dose dependent. Differences in physicochemical status could explain the mortality seen by Sheil et al, especially when using heat treated bacteria. Pereyra and colleagues2 established that the maximal non-lethal quantity of injected live LAB was 5×107 but it can be hypothesised that toxicity may also differ with strain and viability status. Both pro- and anti-inflammatory components of probiotics have been reported to interact with systemic immune cells, showing effects comparable with other well known anti-inflammatory or therapeutic molecules.4 It is therefore most probable that systemic delivery of specific live or killed probiotics may influence the delicate balance between Th1 and Th2 immunity, and subsequently have an impact on local immunity. Clear relationships, however, are not obvious. A first example is the case of subcutaneous CpG DNA that promoted a Th1 response and was able to alleviate some symptoms of DSS colitis but caused inflammation when administered after the onset of colitis.5 Secondly, different experimental models of colitis support a potential benefit of probiotic DNA,3 although it seems very premature to restrict this probiotic effect to nucleic acids only.6

As emphasised by Gosh and colleagues (Gut 2004;53:620–2), approaches involving fractional studies are essential tools to complete the knowledge obtained from in vitro and ex vivo models and assist in understanding the interactions between LAB and the immune system. These studies may reveal common mechanisms active in inflammation, tolerance, and allergy models. Even if this study confirms the importance of the systemic route for certain probiotic activity, we cannot neglect the possible influence of local and innate immunity, the general status of the gut flora, and the role of epithelial cells in the cross talk between both.


We are indebted to Danisco France for financial support.


View Abstract


  • Conflict of interest: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.